The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 313)
Biomarkers of Protein Handling/Autophagy, Exosomes and Lipid, 2019
Mutations (changes) in protein LRRK2 is the main genetic cause of Parkinson's disease (PD). In the past, we found that LRRK2 interacts with ribosomes, cellular protein factories. We then investigated whether LRRK2 changes the way ribosomes work in cellular and pre-clinical models of Parkinson's. We found that ribosomes made 40 percent less protein in Parkinson's models and in skin...
LRRK2 Biology Consortium, 2018
Parkinson's disease (PD) affects nearly any body system, as evidenced by the diversity of its symptoms. While its non-motor symptoms, such as olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD) and gastrointestinal (GI) abnormalities, do not define the disease, they have a large impact on those living with it. In this project, we will use a pre-clinical model o...
Researchers: R. Jeremy Nichols, PhD
Access to Data and Biospecimens, 2018
Uric acid is a chemical produced naturally in the human body. In this project, we aim to investigate whether uric acid is an antioxidant capable of reducing the risk of Parkinson's disease (PD), and in particular, its inherited form caused by a change -- mutation -- in the gene for leucine-rich repeat kinase 2 (LRRK2), the greatest known genetic contributor to PD. In this study...
Researchers: Rachit Bakshi, PhD
Research Grant, 2018
Mutations, or changes, in the genes PRKN and PINK1 cause inherited Parkinson's disease (PD) that starts at an early age. This type of Parkinson's accounts for roughly 13 percent of all early-onset cases. Because of the similarities between the disease caused by one of these mutations (monogenic PD) and the disease with an unknown cause (idiopathic PD), studying monogenic PD could ...
Researchers: Christine Klein, MD
Research Grant, 2018
Mutations (changes) in the gene for the leucine-rich repeat kinase 2 (LRRK2) protein cause inherited Parkinson's disease (PD). Because the activity of LRRK2 is increased in such mutant proteins, drugs have been designed to reduce this activity with the intention of curing PD. However, it is unclear whether these drugs are safe for people because side effects have been observed in p...
Researchers: Elisa Greggio, PhD